Format

Send to

Choose Destination
J Sex Med. 2015 Jun;12(6):1375-80. doi: 10.1111/jsm.12897. Epub 2015 Apr 30.

The nanochannel delivery system for constant testosterone replacement therapy.

Author information

1
The Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
2
Department of Surgery, Houston Methodist Hospital, Houston, TX, USA.
3
NanoMedical Systems Inc., Austin, TX, USA.
4
Department of Urology, Baylor College of Medicine, Houston, TX, USA.
5
Department of Urology, University of Michigan, Ann Arbor, MI, USA.

Abstract

INTRODUCTION:

The goal of testosterone replacement is to provide long-term physiological supplementation at sufficient levels to mitigate the symptoms of hypogonadism.

AIM:

The objective of this work is to determine if the implantable nanochannel delivery system (nDS) can present an alternative delivery strategy for the long-term sustained and constant release of testosterone.

METHODS:

A formulation of common testosterone esters (F1) was developed to enable nanochannel delivery of the low water soluble hormone. In vivo evaluation of testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels by liquid chromatography/mass spectrometry and a multiplex assay, respectively, in castrated Sprague-Dawley rats implanted with nDS-F1 implants or polymeric pellets was performed over a 6-month period. The percent of testosterone concentrations observed that fell within the normal range of testosterone levels for each animal was calculated and used to compare the study groups.

MAIN OUTCOME MEASURES:

Sustain release of testosterone in vivo for over 6 months.

RESULTS:

The subcutaneous release of F1 from nDS implants exhibited sustained in vivo release kinetics and attained stable clinically relevant plasma testosterone levels. Plasma LH and FSH levels were significantly diminished in nDS-F1 implant-treated animals, confirming biological activity of the released testosterone.

CONCLUSIONS:

In conclusion, we demonstrate that nDS-F1 implants represents a novel approach for the treatment of male hypogonadism. Further studies will be performed in view of translating the technology to clinical use.

KEYWORDS:

Androgen Deficiency; Nanochannel Implants; Sustained Release; Testosterone

PMID:
25930087
DOI:
10.1111/jsm.12897
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for MLibrary (Deep Blue)
Loading ...
Support Center